Additional Infant Medication Further Reduces Perinatal HIV Transmission

National Institues of Health (NIH) study findings recently presented at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) found that adding nevirapine or 3TC/nelfinavir to the standard AZT treatment protocol reduced the chances by more than 50% that an infant will develop HIV infection. This study evaluated infants born to mothers from Brazil, South Africa, Argentina and the United States whose HIV infections were not diagnosed until they were in labor.

Click here to learn more.